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454Objective: To evaluate the short- and long-term outcomes of concomitant aortic (AVr) and mitral (MVr) valve
repair.
Methods: This retrospective analysis of prospectively collected data identified patients who had undergone AVr
and MVr surgery from March 1996 to October 2009. Patients were included if they had undergone combined
repair on the aortic and mitral valves. Excluded were those<18 years in whom valve replacement was
performed. Data were collected on the short-term morbidity and mortality (<30 postoperative days),
long-term survival, and freedom from valve-related events and echocardiographic outcomes.
Results: A total of 65 patients underwent AVr and MVr (mean age, 56.4 15.8 years, 46 men). Preoperatively,
30 patients (46.1%) had aortic insufficiency (AI)>2þ, 20 patients had AI 2þ with aortic dilatation (30.7%),
and 4 patients (6.1%) had aortic dilatation only. Of the 65 patients, 57 had tricuspid (87.6%) and 8 had bicuspid
aortic valves (12.3%). All patients had mitral insufficiency preoperatively. One in-hospital death occurred
(1.5%). At discharge, no patient had AI>2þ versus 30 patients preoperatively (P<.001), and 7 patients had
AI>1þ versus 61 patients preoperatively (P< .001). At discharge, the mean left ventricular end-diastolic
diameter was 48  7 mm versus 59  9 mm preoperatively (P < .007), and the mean left ventricular
end-systolic diameter was 33  5 mm versus 38  14 mm preoperatively (P ¼ .36). The mean clinical
follow-up duration was 62  45 months (median, 50; range, 1-177). At the latest follow-up visit, 17 patients
were New York Heart Association class 2 versus 52 patents preoperatively (P<.001). Four cardiac deaths
occurred, and at 1, 5, and 10 years, the freedom from cardiac death was 100%, 93.4%  3.7%, and 88.5%
 5.9%, respectively. Eight valve reinterventions were required, and the freedom from valve reintervention
at 1, 5, and 10 years was 95.3% 2.6%, 91.6% 3.6%, and 78.4% 8.0%, respectively. At 1, 5, and 10 years,
the freedom from AI 2þ was 98.2% 1.7%, 93.4% 3.7%, and 88.3% 5.8% and the freedom from mitral
insufficiency 2þ was 96.4%  2.4%, 93.3%  3.8%, and 93.3%  3.8%, respectively.
Conclusions: Concomitant AVr/MVr is associated with acceptable survival and freedom from valve
reintervention. (J Thorac Cardiovasc Surg 2014;148:454-60)Aortic (AV) and mitral (MV) valve insufficiency coexist in
10% of patients undergoing valvular cardiac surgery.1-3
Traditionally, concomitant disease has been treated
with double valve replacement (DVR), with either
mechanical or bioprosthetic valves. Mechanical valves
require lifelong anticoagulation and, therefore, have
been associated with the risk of major hemorrhage
or thrombosis. Bioprosthetic valves do not require
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Studies have demonstrated that repairing the MV at the
same time as AV replacement (AVR) results in superior
outcomes to DVR.4-6 Specifically, MV repair (MVr)
combined with AVR has been shown to improve overall
survival, reduce valve-related complications, and provide
advantages for patients who are unable to adhere to
intensive anticoagulation regimens.4,6
AVR has generally been considered to be the reference
standard treatment of AV disease, although, recently, the
outcomes of AV repair (AVr) have improved.7-10 The
reasons for this have been multifactorial but not least have
included a better understanding of the functional anatomy
of the AV, the mechanisms underlying aortic insufficiency
(AI), and the development of a classification system that
informs research and standardizes communication among
healthcare professionals.11-13 The primary advantage of
AVr is that the native valve will be preserved, which can
reduce long-term valve-related complications,7,14 prolong
survival,15 and increase quality of life.16 However, the
durability of AVr in the modern era is largely unknown,
and reoperation could be required.15 Despite the potentialery c August 2014
Abbreviations and Acronyms
AI ¼ aortic insufficiency
AV ¼ aortic valve
AVR ¼ aortic valve replacement
AVr ¼ aortic valve repair
AVr/MVr ¼ combined AV and MV repair
DVR ¼ double valve replacement
LV ¼ left ventricular
MI ¼ mitral insufficiency
MV ¼ mitral valve
MVr ¼ mitral valve repair
NYHA ¼ New York Heart Association
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Dbenefits, few studies have evaluated combined AVr and
MVr (AVr/MVr) for concomitant AI and mitral
insufficiency (MI).17,18 The present study, therefore,
assessed the long-term outcomes of combined AV and
MV reconstructive surgery.
METHODS
Study Population
The present study comprised a retrospective analysis of prospectively
collected data from patients undergoing AVr/MVr for coexistent AI and
MI. The procedures were performed from March 1996 to October 2006.
The indications for surgery included patients with primary severe AI/root
dilatation with at least moderate MI, those with severe MI with at least
moderate AI and/or aortic root dilatation, and those with isolated aortic
root dilatation with at least moderate MI. Not all valves had organic
pathologic features. In 39 patients (59.9%), dilatation of the aortic annulus
and/or aorta (type IA, IB, IC, ID) was present without organic aortic valve
pathologic features. Thirty patients (46.1%; type IB, IC, ID) primarily had
aortic dilatation. However, owing to the nature of aortic disease, these
4 subtypes are not mutually exclusive and overlap exists among the 4 types.
Bicuspid and tricuspid AVs were repaired. Excluded were patients
undergoing either MV replacement or AVR and those aged<18 years.
The local institutional review board waived the requirement for participant
consent. All patients routinely underwent echocardiography before surgery
to assess the AVandMV parameters, left ventricular (LV) function, and the
LVand proximal aortic dimensions. Coronary angiography was performed
preoperatively to identify coexistent coronary disease that might require
surgery. Data were collected from the electronic hospital records and
bespoke surgical databases. Data extraction included (1) participant
demographics (age, gender, height, weight, body surface area);
(2) preoperative echocardiographic parameters and New York Heart
Association (NYHA) classification; (3) operative characteristics
(nature and duration of surgical procedure performed, pathologic findings,
concomitant procedures); (4) early postoperative events (mortality,
complications, residual AI or MI and AV gradient), and (5) follow-up
details (follow-up duration, overall survival, need for valve reintervention,
NYHA classification, echocardiographic parameters).
Surgical Technique
The techniques of AVr8,13,14 and MVr19-23 have been previously
reported.
Outcomes
The primary outcome was overall survival, defined as death from any
cause from the date of surgery to the latest follow-up visit. The secondaryThe Journal of Thoracic and Caoutcomes included in-hospital mortality (defined as death from any cause
within 30 days of surgery and/or during the index hospital admission),
early complications (within 30 postoperative days), late valve-related
events (beyond 30 postoperative days), functional outcomes (NYHA
classification), early and late echocardiographic outcomes (AI grade,
AV area, AV gradient, MI grade, LV ejection fraction, LV dimensions,
aortic dimensions), freedom from AI>2þ, freedom from MI>2þ, and
freedom from valve reintervention (any reoperation of the AV or MV,
including transcatheter interventions, during follow-up). Valve-related
complications were determined by the occurrence of reoperation, bleeding,
endocarditis, and thromboembolism, with the help of comprehensive
cardiology follow-up clinics, where clinical and echocardiographic
parameters were assessed at regular intervals. A composite outcome of
freedom from both valve-related mortality and late valve-related events
was calculated.
Statistical Analysis
Statistical analysis was performed using the Statistical Package for
Social Sciences, version 16.0 (SPSS, Inc, Chicago, Ill). Data are presented
as the mean  standard deviation or median and range, as appropriate.
To compare the continuous variables, the Student unpaired t test or
Mann-Whitney U test was used. For categorical variables, the chi-square
or Fisher’s exact test were used. The Kaplan-Meier method was used to
evaluate time-dependent variables, and comparisons were made between
groups using the log-rank test of equality. P < .05 was considered
statistically significant.
RESULTS
Patients
A total of 65 patients underwent AVr/MVr from March
1996 to October 2006 (Table 1). The mean patient age
was 57.4  15.8 years (median, 59.9; range, 16.4-84.1),
and most patients were men (n ¼ 46, 70.7%). Preoperative
echocardiography demonstrated that the mean ejection
fraction of the included patients was 60%  13%, and 12
patients (18.4%) had evidence of impaired LV ejection
fraction preoperatively (<50%). The indications for AVr
were AI >2þ (n ¼ 30, 46.1%), AI 2þ with aortic
dilatation (n ¼ 20, 30.7%), and aortic dilatation only
(n ¼ 4, 6.1%). Six patients (9.2%) had previously
undergone cardiac surgery (coronary artery bypass grafting
in 2, repair of aortic coarctation in 2, ventricular septal
defect closure, pulmonary valvotomy, and tricuspid valve
repair in 1, and MVr in 1). The underlying AV pathologic
findings included degeneration (n ¼ 46; 70.7%), bicuspid
AV (n ¼ 8; 12.3%), Marfan’s disease (n ¼ 4; 6.1%),
rheumatic heart disease (n ¼ 5; 7.7%), and infective
endocarditis (n ¼ 2; 3%). The etiology of MV disease
was degenerative (n ¼ 33; 50.7%), rheumatic (n ¼ 12;
18.4%), endocarditis (n ¼ 4; 6.1%), functional (n ¼ 10,
15.3%), ischemic (n ¼ 2, 3.0%), and other findings
(n ¼ 4; 6.1%).
Operative Details
The operative details are listed in Table 2. The mean
cardiopulmonary bypass time was 127.6  45.4 minutes,
and the mean aortic crossclamp time was 109.9  50.5
minutes. The most frequently performed AV proceduresrdiovascular Surgery c Volume 148, Number 2 455
TABLE 1. Summary of preoperative characteristics (n ¼ 65)
Characteristic Value
Age (y) 56.4  15.8
Male gender 46 (70.7)
Preoperative echocardiography
Ejection fraction (%) 60  13
LVEDD>60 mm 26 (40.0)
LVESD>40 mm 20 (30.7)
AI 2þ only 30 (46.1)
AI 2þ and dilatation 20 (30.7)
Dilatation only 4 (6.1)
Functional AV classification
IA 9 (13.8)
IB 15 (23.1)
IC 12 (18.4)
ID 3 (4.6)
II 23 (35.4)
III 14 (21.5)
Etiology of AI
Degenerative 46 (70.7)
Bicuspid AV 8 (12.3)
Marfan’s disease 4 (6.1)
Rheumatic heart disease 5 (7.7)
Infective endocarditis 2 (3.0)
Etiology of MI
Degenerative 33 (50.7)
Rheumatic heart disease 12 (18.4)
Infective endocarditis 4 (6.1)
Annular dilatation 10 (15.3)
Ischemic 2 (3.0)
Other 4 (6.1)
Data presented as mean  standard deviation or n (%). LVEDD, Left ventricular
end-diastolic diameter; LVESD, left ventricular end-systolic diameter; AV, aortic
valve; AI, aortic insufficiency; MI, mitral insufficiency.
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AV-sparing procedure plus cusp repair (n ¼ 9, 13.8%), an
AV-sparing procedure alone (n ¼ 8, 12.3%), and
annuloplasty only (n ¼ 8, 12.3%). Sixteen David
(24.6%) and five Yacoub (7.7%) procedures were
performed. The MV procedures included annuloplasty
ring insertion (n ¼ 52, 80.0%), cusp resection (n ¼ 18,
27.7%), and neochordae formation (n ¼ 10, 15.4%).
Concomitant procedures were performed in 21 patients
(32.3%). These included tricuspid valve repair (n ¼ 10),
coronary artery bypass grafting (n ¼ 7), coronary artery
bypass grafting plus a Dor procedure (n ¼ 1), tricuspid
valve repair plus a maze procedure (n¼ 1), maze procedure
(n ¼ 1), and excision of a left atrial myxoma (n ¼ 1).Early Postoperative Outcomes
One in-hospital mortality occurred (1.5%). Early
complications (<30 days after surgery) included atrial
fibrillation (n ¼ 31, 47.7%), re-exploration for hemorrhage
(n ¼ 5, 7.7%), acute renal failure requiring hemofiltration
(n ¼ 2, 3.1%), lower respiratory tract infection (n ¼ 2,456 The Journal of Thoracic and Cardiovascular Surg3.1%), cerebrovascular events (n ¼ 2, 3.1%), pericardial
effusion (n ¼ 1, 1.5%), and pleural effusion (n ¼ 1,
1.5%). No cases of deep sternal wound infection or early
infective endocarditis developed. Two patients required
permanent pacemaker insertion (one for complete heart
block and the other for symptomatic slow atrial fibrillation).
One patient (end-systolic diameter, 46 mm) who had
undergone AVr (subcommissural annuloplasty times 3
plus triangular resection of the right coronary cusp) for
severe AI plus MVr (bovine pericardial patch to anterior
cusp) required early AV reoperation (biologic valve
replacement) 8 days after surgery. At discharge, no patient
had AI>2þ versus 30 patients preoperatively (P< .001)
and 7 patients had AI>1þ versus 61 patients preoperatively
(P>.001). The peak AV gradient was 13.6  12.4 mm Hg.
The mean LV end-diastolic diameter at discharge was
48  7 mm versus 59  9 mm preoperatively (P<.007),
and the mean LV end-systolic diameter was 33  5 mm
versus 38  14 mm preoperatively (P ¼ .36).
Late Postoperative Outcomes
The mean clinical follow-up was 62  45 months
(median, 50; range, 1-177). The clinical and echocardio-
graphic follow-up data were 100% complete. During the
study period, 9 late deaths occurred (>30 days after
surgery). The cause of late death included cardiac disease
in 3 and cerebral tumor, colorectal cancer, multiple
myeloma, myelodysplasia, pneumonia, and multiorgan
dysfunction in 1 each. Overall survival at 1, 5, and 10 years
was 98.5% 1.5%, 85.9% 5.0%, and 67.3% 11.1%,
respectively (Figure 1, A). Freedom from cardiac death
was 100% at 1 year, 93.4%  3.7% at 5 years, and
88.5%  5.9% at 10 years (Figure 1, B).
Late complications (>30 days after surgery) occurred in
7 patients. Six valve-related events occurred, including
reoperation in 4 (3 for aortic insufficiency and 1 for mitral
stenosis), AV endocarditis in 1, and thromboembolism,
leading to cerebrovascular accident, in 1 during the
follow-up period. Freedom from valve-related events was
96.9%  2.1%, 92.4%  2.7%, and 82.8%  7.4% at
1, 5, and 10 years, respectively (Figure 2, A). In addition,
freedom from the composite outcome of valve-related
events and valve-related mortality was 96.9%  2.1%,
86.0%  5.0%, and 77.0%  7.6% at 1, 5, and 10 years,
respectively (Figure 2, B). Freedom from valve
reintervention at 1, 5, and 10 years was 95.3%  2.6%,
91.6%  3.6%, and 78.4% 8.0%, respectively
(Figure 3, B). Cardiac reoperations were necessary in
10 patients, 1 of which was performed within 30 days of
the primary intervention. These procedures included 8
valve-related reoperations and 2 cardiac transplantations.
The valve-related reoperations included 4 MV replace-
ments (for mitral stenosis in 2, for mitral regurgitation
in 1, and for infective endocarditis in 1), 2 AVRs, andery c August 2014
TABLE 2. Summary of operative characteristics (n ¼ 65)
Characteristic Value
Cardiopulmonary bypass time (min) 127.6  45.4
Crossclamp time (min) 109.9  50.5
Bicuspid AV cusp pathologic features
Cusp prolapse 8 (12.3)
Coronary cusp 7 (10.8)
Coronary and noncoronary cusp 1 (1.5)
Tricuspid AV cusp pathologic features
Cusp prolapse 21 (32.3)
Noncoronary cusp 4 (6.2)
Right coronary cusp 10 (15.4)
Left coronary cusp 3 (4.6)
Right and left coronary cusps 1 (1.5)
Noncoronary and right coronary cusps 3 (4.6)
Aortic valve procedures (n ¼ 65)
Cusp repair 44 (67.7)
Annuloplasty 42 (64.6)
Valve sparing 24 (36.9)
Ascending aorta replacement 15 (23.0)
Bicuspid aortic valve repair (n ¼ 8)
Raphe repair 7 (87.5)
Shaving 1 (12.5)
Gore-Tex reinforcement 5 (62.5)
Direct suture 5 (62.5)
Plication 2 (25.0)
Subcommissural annuloplasty 5 (62.5)
Tricuspid aortic valve repair (n ¼ 57)
Plication 16 (28.0)
Triangular resection 1 (1.7)
Gore-Tex reinforcement 6 (10.5)
Subcommissural annuloplasty 43 (75.4)
Sinotubular junction plication 8 (14.0)
Shaving and decalcification 13 (22.8)
Decalcification 3 (5.2)
Concomitant procedures
TV repair 10 (15.4)
CABG 7 (10.8)
CABG þ Dor 1 (1.5)
TV repair þ maze 1 (1.5)
Maze 1 (1.5)
Excision left atrial myxoma 1 (1.5)
Aortic prosthesis
Straight graft 15 (23.1)
Valsalva 9 (13.8)
Aortic prosthesis size (mm) 28.0  2.6
Mitral valve procedures
Annuloplasty 52 (80.0)
Cusp resection 18 (27.7)
Neochordae 10 (15.4)
Closure of perforation 2 (3.1)
Commissuroplasty 6 (9.2)
Annular decalcification 5 (7.7)
Chordal transfer 1 (1.5)
Papillary muscle splitting/repositioning 3 (4.6)
Alfieri 5 (7.7)
Tricuspid autograft 3 (4.6)
(Continued)
TABLE 2. Continued
Characteristic Value
Flip-over 1 (1.5)
Patch augmentation 5 (7.7)
Sliding plasty 6 (9.2)
Annular plication 4 (6.2)
Other 2 (3.1)
Ring annuloplasty size (mm) 31.3  3.0
Data presented as mean standard deviation or n (%). AV, Aortic valve; TV, tricuspid
valve; CABG, coronary artery bypass grafting.
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Freedom from cardiac reoperation was 95.3%  2.6%,
87.5%  4.5%, and 74.3%  8.2% at 1, 5, and 10 years,
respectively (Figure 3, A).
The mean echocardiographic follow-up duration was
57  45 months (median, 49; range, 1-169). At the final
follow-up visit, 4 patients had AI>2þ, and the peak aortic
gradient was 16.9  10.7 mm Hg. No difference was found
between AI 1þ at discharge compared with AI 1þ at latest
follow-up (P ¼ .10). The mean gradient of the AVs was
5.9  7.5 mm Hg at discharge versus 12.45  7.48 mm
Hg at the latest follow-up visit (P ¼ .2). At 1, 5, and
10 years, the freedom from AI 2þ was 98.2%  1.7%,
93.4%  3.7%, and 88.3%  5.8%, respectively
(Figure 4, A). One patient had MI grade>2þ at the latest
follow-up examination, with freedom from MI 2þ of
96.4%  2.4%, 93.3%  3.8%, and 93.3%  3.8% at
1, 5, and 10 years, respectively (Figure 4, B). At the
latest follow-up visit, 17 of 65 patients were NYHA class
2þ postoperatively compared with 52 of 65 patients
preoperatively (P<.001).DISCUSSION
Surgical interventions that preserve the native heart
valves have emerged as attractive alternatives to valve
replacement in recent years. The perceived benefits of
valve-sparing procedures have been that they negate the
need for lifelong anticoagulation (in contrast to mechanical
prostheses) and can be associated with fewer valve-related
complications, including hemorrhage, thromboembolism,
endocarditis, and degeneration.7 Concerns have, however,
been raised about the durability of the repairs and the
need for reoperation and valve replacement at a later date.
Although numerous studies have reported the outcomes
for single valve repair, especially for the MV,4-6 little
previous work has considered the effectiveness of dual
valve repair.17,18 The present study, therefore, examined
the outcomes for AVr/MVr. AVr/MVr was shown to be
safe in the short term and to have acceptable overall
survival and freedom from valve-related events for
10 years after the primary surgery. In addition, few
patients required valve-related cardiac reoperation during
the follow-up period. This suggests that AVr/MVr is anrdiovascular Surgery c Volume 148, Number 2 457
FIGURE 1. A, Kaplan-Meier curve showing overall survival (number
of patients at risk at different intervals given below the curve).
B, Kaplan-Meier curve showing cardiac survival (number of patients at
risk at different intervals given below the curve).
FIGURE 2. A, Kaplan-Meier curve showing freedom from valve-related
events (number of patients at risk at different intervals given below
the curve). B, Kaplan-Meier curve showing freedom from valve
related-events (VRE) and valve-related mortality (VRM) (number of
patients at risk at different intervals given below the curve).
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with concomitant AI and MI.
Gillinov and colleagues17 conducted the largest study to
date to investigate the outcomes of AVr/MVr. In their
retrospective case series of 158 patients, they reported low
rates of operative mortality (3%) and overall survival of
93%, 82%, and 62% at 1, 5, and 10 years postoperatively.
Late death was shown to be associated with old age, aortic
stenosis, and LV dysfunction on multivariate analysis.17
In addition, they demonstrated acceptable freedom from
reoperation, with a rate of 94%, 82%, and 65% at 1, 5,
and 10 years, respectively. The risk factors for reoperation
included severe AI, aortic cusp shaving, mitral valve
chordal transfer, and bovine pericardial annuloplasty.
Most reoperations occurred in patients with rheumatic
disease, who included almost 50% of their cohort.
However, rheumatic etiology per se did not emerge as a458 The Journal of Thoracic and Cardiovascular Surgrisk factor for reoperation.17 Valve-related complications
were also low in this series with freedom from
valve-related complications of 99%, 95%, and 94% at
1, 5, and 10 years, respectively.17 In the case of severe
rheumatic disease, durability was limited for both AVs
and MVs.8,17,19,22 Despite our aggressive approach to the
repair of rheumatic valves, only 8% and 18% of our AVs
and MVs, respectively, were rheumatic. The likely reason
for this was that we studied surgery for MI; thus, patients
who had undergone surgery for mitral stenosis secondary
to rheumatic heart disease were excluded. In the triple
valve repair series by Grinda and colleagues,24 about one
half of the patients had rheumatic disease; however, their
results were good. Although degenerative MV disease
affecting the anterior cusp of the MV has been suggested
as a risk factor for reoperation,17 we have not found
this in our single valve series.21,23 In a small series ofery c August 2014
FIGURE 3. A, Kaplan-Meier curve showing freedom from cardiac
reoperation (number of patients at risk at different intervals given below
the curve). B, Kaplan-Meier curve showing freedom from valve
reoperation in all patients (number of patients at risk at different intervals
given below the curve).
FIGURE 4. A, Kaplan-Meier curve showing freedom from aortic
insufficiency (AI) 2þ (number of patients at risk at different intervals given
below the curve). B, Kaplan-Meier curve showing freedom from mitral
insufficiency (MI) 2þ (number of patients at risk at different intervals given
below the curve).
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mortality or episodes of valve-related complications
occurred1 year after surgery. These outcomes are broadly
similar to those observed in the present study and highlight
that double valve repair is a safe, feasible, and effective
alternative to DVR or AVR plus MVr.
Studies have also compared the outcomes for DVR with
those for AVR plus MVr. In another study from the
Cleveland Clinic, overall survival was significantly better
for the patients treated with AVR plus MVr than for those
treated with DVR.4 In the AVR plus MVr group, overall
survival at 5 and 10 years was 79% and 63%, respectively,
and these data are comparable to those in the present study.
In addition, freedom from MV reoperation was slightly
worse after MVr than after DVR with mechanical prosthe-
ses. However, when bioprosthetic valves were used for
MVR, freedom from MV reoperation was considerablyThe Journal of Thoracic and Cabetter in the MVr group. In that study, 70% of both AVs
and MVs were rheumatic, and the study also included
stenotic valves. Hence, the study population was different
from the population included in our study. Other studies
of similar design have shown AVR plus MVr to be associ-
ated with less frequent major hemorrhage5 and better
event-free survival6 compared with DVR. These studies
highlight that MVr plus AVR is superior to DVR; however,
studies are required to make comparisons with AVr/MVr. It
could be hypothesized that AVr/MVr would confer addi-
tional benefits to MVr plus AVR, because both native valves
would be retained, and the incidence of valve-related events
might be even lower. A repair strategy seems to confer sur-
vival benefit in double-valve disease; however, additional
studies are needed to address the issue of durability, such
as has been done to a considerable extent in single valve
disease, for both the MV, and to a lesser degree, the AV.rdiovascular Surgery c Volume 148, Number 2 459
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effectiveness of AVr/MVr; therefore, it is important to
consider some of its limitations. Although the techniques
involved in valve repair have evolved significantly since
their inception, relatively few centers routinely perform
such procedures. A learning curve exists for delivering
such interventions, and in many centers without specialist
expertise, concomitant AI and MI might best be managed
with techniques individual surgeons are most adept at
performing, whether DVR or AVR plus MVr. Wider
training internationally in the nuances of AVr/MVr is,
therefore, warranted to fully evaluate the potential of this
treatment option. Second, although the results of the present
study can be contrasted with other studies of DVR or AVR
plus MVr, meaningful and valid comparisons can only be
undertaken within the context of larger multi-institutional
studies. This, however, might entail additional population
heterogeneity and disparate treatment recommendations
lacking equipoise, causing selection bias and inconsistent
outcomes assessments.25
CONCLUSIONS
The present study has demonstrated that AVr/MVr has
acceptable long-term survival, freedom from valve-related
complications, and acceptable durability. It is, therefore,
recommended for use in patients with concomitant AI and
MI. Future comparative studies are required to confirm
the effectiveness of AVr/MVr against procedures involving
valve replacement.
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